Nevirapin Heumann (Nevirapine)

Nevirapine, the active ingredient in Nevirapin Heumann, is a Non-nucleoside reverse transcriptase inhibitor (NNRTI) presented as an oral dosage form for oral use. It treats HIV‑1 infection in adults and adolescents, reducing viral replication as part of combination antiretroviral therapy and is indicated for patients requiring a potent NNRTI component.

GNH USA supplies Nevirapin Heumann as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nevirapine is used in the management of HIV‑1 infection, a viral disease that attacks the immune system.

- Treatment‑naïve patients: achieves virologic suppression when combined with other antiretrovirals. - Patients on established therapy: maintains viral load reduction as part of salvage regimens. - Co‑infection with hepatitis B or C: contributes to overall antiviral control within combination therapy.

Nevirapine may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Rash: mild to moderate skin eruptions. - Nausea: occasional upset stomach. - Fatigue: feeling of tiredness. - Headache: mild to moderate intensity. - Dizziness: transient light‑headedness. - Abdominal pain: mild discomfort.

Serious or Rare Side Effects: - Stevens‑Johnson syndrome: severe skin reaction requiring immediate medical attention. - Hepatic failure: signs of liver injury such as jaundice. - Severe hypersensitivity: fever, eosinophilia, or organ involvement. - Neutropenia: low white‑blood‑cell count increasing infection risk. - Anemia: reduced red blood cells causing fatigue.

Before initiating therapy, clinicians should assess patient history and monitor for specific concerns.

- Liver monitoring: check hepatic function tests regularly. - Rash vigilance: discontinue if severe or progressing. - Hypersensitivity: avoid in patients with known allergy to nevirapine. - Hepatic impairment: use with caution in patients with existing liver disease. - Drug‑induced hepatotoxicity: avoid concomitant use of other hepatotoxic agents when possible. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Nevirapine can alter the plasma levels of several co‑administered medicines, requiring careful management.

Major Interactions (Avoid): - Rifampin: markedly reduces nevirapine concentrations. - St. John’s wort: induces metabolism, lowering efficacy. - Carbamazepine: decreases nevirapine exposure.

Moderate Interactions (Monitor Closely): - Azole antifungals (e.g., ketoconazole): may increase nevirapine levels. - Oral contraceptives: efficacy may be reduced, consider alternative contraception.